nach oben

Journal of Natural Medicines

Erschienen in:

01.04.2015 | Original Paper

The TLR2 agonist in polysaccharide-K is a structurally distinct lipid which acts synergistically with the protein-bound β-glucan

verfasst von: Kenneth Quayle, Catherine Coy, Leanna Standish, Hailing Lu

Erschienen in: Journal of Natural Medicines | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Protein-bound polysaccharide-K (Krestin; PSK) is a hot-water extract of Trametes versicolor with immune stimulatory activity. It has been used for the past 30 years and has demonstrated anti-tumor efficacy in multiple types of cancer. The ability of PSK to activate dendritic cells and T cells is dependent on its ability to stimulate Toll-like receptor 2 (TLR2), yet it remains unknown which structural component within PSK activates TLR2. The purpose of this study was to identify the TLR2 agonist within PSK and understand its role in the overall mechanism of PSK’s immunogenic activity. TLR2 activity was eliminated by treatment with lipoprotein lipase but not by trypsin or lyticase. Rapid centrifugation of PSK can separate the fraction with TLR2 agonist activity from the soluble β-glucan fraction. To study the potential interaction between the β-glucan component and the lipid component, we labeled the soluble β-glucan with fluorescein. Uptake of the labeled β-glucan by J774A macrophages and JAWSII dendritic cells was inhibited by anti-Dectin-1 antibody but not by anti-TLR2 antibody, confirming that Dectin-1 is the receptor for β-glucan. Interestingly, pre-treatment of JAWSII cells with the TLR2-active lipid fraction significantly enhanced the uptake of the soluble β-glucan, indicating the synergy between the TLR2 agonist component and the β-glucan component. Altogether, these results present evidence that PSK has two active components—the well-characterized protein-bound β-glucan and a previously unreported lipid—which work synergistically via the Dectin-1 and TLR2 receptors.

Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K (1984) Krestin (PSK). Cancer Treat Rev 11:131–155CrossRefPubMed

Maehara Y, Tsujitani S, Saeki H, Oki E, Yoshinaga K, Emi Y, Morita M, Kohnoe S, Kakeji Y, Yano T, Baba H (2012) Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®): review of development and future perspectives. Surg Today 42:8–28CrossRefPubMedCentralPubMed

Lu H, Yang Y, Gad E, Wenner CA, Chang A, Larson ER, Dang Y, Martzen M, Standish LJ, Disis ML (2011) Polysaccharide Krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res 17:67–76CrossRefPubMedCentralPubMed

Engel A L, Sun G-C, Gad E, Rastetter L R, Strobe K, Yang Y, Dang Y, Disis M L, Lu H (2013) Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant. Immunobiology 218(12):1468-76

Hotta T, Enomoto S, Yoshikumi C, Ohara M, Ueno S (1981) Protein-bound polysaccharides. Kureha Chemical Industry Co. Ltd, Japan

Ohtsuka S, Ueno A, Yoshikumi C, Hirose F, Omura Y, Wada T, Fujii T, Takahashi E (1971) Polysaccharides with anticancer activity. Kureha Chemical Industry Co. Ltd, European patent office

Muller A, Pretus HA, McNamee RB, Jones EL, Browder IW, Williams DL (1995) Comparison of the carbohydrate biological response modifiers Krestin, schizophyllan and glucan phosphate by aqueous size exclusion chromatography with in-line argon-ion multi-angle laser light scattering photometry and differential viscometry detectors. J Chromatogr B Biomed Appl 666:283–290CrossRefPubMed

Ren L, Perera C, Hemar Y (2012) Antitumor activity of mushroom polysaccharides: a review. Food Funct 3:1118–1130CrossRefPubMed

Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Ann Rev Immunol 21:335–376CrossRef

10.

Engel AL, Holt GE, Lu H (2011) The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Rev Clin Pharmacol 4:275–289CrossRefPubMedCentralPubMed

11.

Pasare C, Medzhitov R (2004) Toll-like receptors and acquired immunity. Semin Immunol 16:23–26CrossRefPubMed

12.

Sheu F, Chien PJ, Hsieh KY, Chin KL, Huang WT, Tsao CY, Chen YF, Cheng HC, Chang HH (2009) Purification, cloning, and functional characterization of a novel immunomodulatory protein from Antrodia camphorata (bitter mushroom) that exhibits TLR2-dependent NF-kappaB activation and M1 polarization within murine macrophages. J Agric Food Chem 57:4130–4141CrossRefPubMed

13.

Yamanaka D, Motoi M, Ishibashi K, Miura NN, Adachi Y, Ohno N (2012) Effect of Agaricus brasiliensis-derived cold water extract on Toll-like receptor 2-dependent cytokine production in vitro. Immunopharmacol Immunotoxicol 34:561–570CrossRefPubMed

14.

Brown GD, Herre J, Williams DL, Willment JA, Marshall ASJ, Gordon S (2003) Dectin-1 mediates the biological effects of β-glucans. J Exp Med 197:1119–1124CrossRefPubMedCentralPubMed

15.

Fang J, Wang Y, Lv X, Shen X, Ni X, Ding K (2012) Structure of a beta-glucan from Grifola frondosa and its antitumor effect by activating dectin-1/Syk/NF-kappaB signaling. Glycoconj J 29:365–377CrossRefPubMed

16.

Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, Qian K, Vasilakos J, Saijo S, Iwakura Y, Yannelli JR, Yan J (2011) Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived beta-glucans. Blood 117:6825–6836CrossRefPubMedCentralPubMed

17.

Sullivan R, Smith JE, Rowan NJ (2006) Medicinal mushrooms and cancer therapy: translating a traditional practice into Western medicine. Perspect Biol Med 49:159–170CrossRefPubMed

18.

Normile D (2003) Asian medicine. The new face of traditional Chinese medicine. Science 299:188–190CrossRefPubMed

19.

Wasser SP (2011) Current findings, future trends, and unsolved problems in studies of medicinal mushrooms. Appl Microbiol Biotechnol 89:1323–1332CrossRefPubMed

20.

Manders EMM, Verbeek FJ, Aten JA (1993) Measurement of co-localization of objects in dual-colour confocal images. J Microsc 169:375–382CrossRef

21.

Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, Wong SY, Gordon S (2002) Dectin-1 is a major beta-glucan receptor on macrophages. J Exp Med 196:407–412CrossRefPubMedCentralPubMed

22.

Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570CrossRefPubMed

23.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964CrossRefPubMed

24.

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133CrossRefPubMed

25.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144CrossRefPubMedCentralPubMed

26.

27.

Falch BH, Espevik T, Ryan L, Stokke BT (2000) The cytokine stimulating activity of (1 → 3)-β-D-glucans is dependent on the triple helix conformation. Carbohydr Res 329:587–596CrossRefPubMed

28.

Bohn JA, BeMiller JN (1995) (1 → 3)-β-d-Glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydr Polym 28:3–14CrossRef

29.

Zhang L, Li X, Xu X, Zeng F (2005) Correlation between antitumor activity, molecular weight, and conformation of lentinan. Carbohydr Res 340:1515–1521CrossRefPubMed

30.

Günç Ergönül P, Akata I, Kalyoncu F, Ergönül B (2013) Fatty acid compositions of six wild edible mushroom species. ScientificWorldJournal 2013:163964

31.

Brown GD, Gordon S (2001) Immune recognition. A new receptor for beta-glucans. Nature 413:36–37CrossRefPubMed

32.

Mansour MK, Tam JM, Khan NS, Seward M, Davids PJ, Puranam S, Sokolovska A, Sykes DB, Dagher Z, Becker C, Tanne A, Reedy JL, Stuart LM, Vyas JM (2013) Dectin-1 activation controls maturation of beta-1,3-glucan-containing phagosomes. J Biol Chem 288:16043–16054CrossRefPubMedCentralPubMed

33.

Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, Qian K, Vasilakos J, Saijo S, Iwakura Y, Yannelli J R, Yan J (2011) Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans. Blood 117(25):6825-36

34.

Brown GD, Gordon S (2003) Fungal β-glucans and mammalian immunity. Immunity 19:311–315CrossRefPubMed

35.

Timmermans K, Plantinga TS, Kox M, Vaneker M, Scheffer GJ, Adema GJ, Joosten LAB, Netea MG (2013) Blueprints of signaling interactions between pattern recognition receptors: implications for the design of vaccine adjuvants. Clin Vaccine Immunol 20:427–432CrossRefPubMedCentralPubMed

36.

Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM (2003) Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 197:1107–1117CrossRefPubMedCentralPubMed

37.

Pang Z-J, Zhou M, Chen Y, Wan J (1998) A protein-bound polysaccharide synergistic with lipopolysaccharide induces nitric oxide release and antioxidant enzyme activities in mouse peritoneal macrophages. Am J Chin Med 26:133–141CrossRefPubMed

38.

Toge T, Yamaguchi Y (2000) Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count. Oncol Rep 7:1157–1161PubMed

39.

Kidd PM (2000) The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 5:4–27PubMed

40.

Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Sugai H, Akaike H, Fujii H (2008) Protein-bound polysaccharide K partially prevents apoptosis of circulating T cells induced by anti-cancer drug S-1 in patients with gastric cancer. Oncology 74:143–149CrossRefPubMed

41.

Koda K, Miyazaki M, Sarashina H, Suwa T, Saito N, Suzuki M, Ogawa K, Watanabe S, Kodaira S, Nakazato H (2003) A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. Int J Oncol 23:165–172PubMed

42.

Shibata M, Nezu T, Kanou H, Nagata Y, Kimura T, Takekawa M, Ando K, Fukuzawa M (2002) Immunomodulatory effects of low dose cis-diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer. Cancer Invest 20:166–173CrossRefPubMed

43.

Morimoto T, Ogawa M, Orita K, Sugimachi K, Toge T, Dohi K, Nomura Y, Monden Y, Ogawa N (1996) Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon cooperative study group of adjuvant chemoendocrine therapy for breast cancer (ACETBC) of Japan. Eur J Cancer 32A:235–242CrossRefPubMed

44.

Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study group of immunochemotherapy with PSK for gastric cancer. Lancet 343:1122–1126CrossRefPubMed

45.

Toi M, Hattori T, Akagi M, Inokuchi K, Orita K, Sugimachi K, Dohi K, Nomura Y, Monden Y, Hamada Y et al (1992) Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi–Nippon group of the adjuvant chemoendocrine therapy for breast cancer organization. Cancer 70:2475–2483CrossRefPubMed

46.

Pugh ND, Tamta H, Balachandran P, Wu X, Howell JL, Dayan FE, Pasco DS (2008) The majority of in vitro macrophage activation exhibited by extracts of some immune enhancing botanicals is due to bacterial lipoproteins and lipopolysaccharides. Int Immunopharmacol 8:1023–1032CrossRefPubMedCentralPubMed

47.

Tamta H, Pugh ND, Balachandran P, Moraes R, Sumiyanto J, Pasco DS (2008) Variability in in vitro macrophage activation by commercially diverse bulk echinacea plant material is predominantly due to bacterial lipoproteins and lipopolysaccharides. J Agric Food Chem 56:10552–10556CrossRefPubMedCentralPubMed

48.

Yadav M, Schorey JS (2006) The beta-glucan receptor dectin-1 functions together with TLR2 to mediate macrophage activation by mycobacteria. Blood 108:3168–3175CrossRefPubMedCentralPubMed

49.

Fisher M, Yang LX (2002) Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res 22:1737–1754PubMed

Titel: The TLR2 agonist in polysaccharide-K is a structurally distinct lipid which acts synergistically with the protein-bound β-glucan
verfasst von: Kenneth Quayle
Catherine Coy
Leanna Standish
Hailing Lu
Publikationsdatum: 01.04.2015
Verlag: Springer Japan
Erschienen in: Journal of Natural Medicines / Ausgabe 2/2015
Print ISSN: 1340-3443
Elektronische ISSN: 1861-0293
DOI: https://doi.org/10.1007/s11418-014-0879-z

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

The TLR2 agonist in polysaccharide-K is a structurally distinct lipid which acts synergistically with the protein-bound β-glucan

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Effects of curine in HL-60 leukemic cells: cell cycle arrest and apoptosis induction

Intestinal bacterial metabolism and anti-complement activities of three major components of the seeds of Entada phaseoloides

Pharmacokinetic interaction between Kaempferia parviflora extract and sildenafil in rats

Antinociceptive and anti-inflammatory activity of the siaresinolic acid, a triterpene isolated from the leaves of Sabicea grisea Cham. & Schltdl. var. grisea

Inhibitory effect of Moutan Cortex aqueous fraction on mast cell-mediated allergic inflammation

Antifungal activity of the essential oil of Angelica major against Candida, Cryptococcus, Aspergillus and dermatophyte species